Scientists Begin Phase 2 Trial of a Zika Vaccine

Scientists Begin Phase 2 Trial of a Zika Vaccine

A vaccine developed by scientists at the National Institute for Allergy and Infectious Diseases is being tested. If all goes well with the Phase 2 work, scientists may see clues by the end of this year as to whether the vaccine provides protection against Zika, NIAID Director Dr. Anthony Fauci said Friday.

Subscribe
April 4, 2017

Scientists have begun a Phase 2 trial of a vaccine to protect against the Zika virus, the first time an experimental Zika vaccine has gone beyond initial safety testing, Stat News reported.

The trial is testing a vaccine developed by scientists at the National Institute for Allergy and Infectious Diseases. If all goes well with the Phase 2 work, scientists may see clues by the end of this year as to whether the vaccine provides protection against Zika, NIAID Director Dr. Anthony Fauci said Friday.

The clinical trial involves a DNA-based vaccine, in which proteins from the Zika virus are placed into small pieces of DNA. Although there are several DNA vaccines licensed for agricultural use, there are currently no licensed DNA vaccines for use in humans.

The Phase 2 trial began Wednesday at Baylor College of Medicine in Houston, one of 11 sites involved in the study. Most of the others are outside the continental US, in places where Zika is or has been transmitting. They include Puerto Rico, Mexico, Costa Rico, Brazil, and Peru.

Click here to read more.

Source: Stat News